Farxiga vs Jakafi
Side-by-side drug price comparison from Medicare Part D data
Verdict
Farxiga costs 98% less per claim than Jakafi ($266.00 vs $11432.00). Farxiga has a generic alternative available. Total Medicare spending: Farxiga at $3.0B vs Jakafi at $2.7B.
| Metric | Farxiga | Jakafi |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $266* | $11,432 |
| Total Medicare Spending Total Medicare Part D spending on this drug | $3.0B | $2.7B |
| Total Claims | 11,240,000 | 236,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | 31.5% | 11.2%* |
| Generic Available | Yes | No |
| Condition | Diabetes | Cancer |
| Total Beneficiaries | 1,340,000 | 22,000 |
Farxiga costs 98% less per claim than Jakafi ($266.00 vs $11432.00). Farxiga has a generic alternative available. Total Medicare spending: Farxiga at $3.0B vs Jakafi at $2.7B.
Explore More
Comparing Farxiga and Jakafi on U.S. Medicare prescription-drug pricing requires lining up the underlying CMS Medicare Part D Drug Spending data data side by side. The table above runs the comparison on the canonical fields; the narrative below identifies the factor or factors that drive the most meaningful difference between the two.
For households or analysts using this comparison as a decision input, the right framing is usually not "which is better" in aggregate but "which is better for the specific decision in front of you." CMS Medicare Part D Drug Spending data captures the raw data; the framing depends on whether the question is investment, residency, planning, or research.
Source: CMS Medicare Part D Spending, 2026.